APTX Apotex Health Corp.
Apotex Health Corp. operates as a pharmaceutical manufacturing company in Canada, the United States, Mexico, and India. The company develops, manufactures, and distributes a portfolio of prescription and generic pharmaceuticals, oncology biosimilar pharmaceuticals, branded specialty pharmaceuticals, and branded consumer health and wellness products. Apotex Health Corp. has a strategic partnership with Halo Pharmaceutical, Inc. The company was formerly known as Artemis Parent, Inc. and changed its name to Apotex Health Corp. in May 2026. The company was founded in 1974 and is headquartered in Toronto, Canada. Apotex Health Corp. operates as a subsidiary of SK Artemis Holdings, II, LLC.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Apotex Health (TSE: APTX)
›
Apotex Health (TSE: APTX) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 6,000 employees.
The shares were at 41.70 CAD on 19 November 2026. Its 52-week range is 26.05 CAD to 42.31 CAD: the price is 1.4% below the high and 60.1% above the low.
Its market capitalisation is 9.55B CAD. It pays a dividend yielding 0.15%, against a median of 1.90% among the dividend payers in that peer group.
Apotex Health reports return on equity of -67.0%, an operating margin of 19.4% and revenue up 1.1% year over year.
Its debt exceeds its cash by 2.86B CAD. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 44.13 CAD is 5.8% above the current price. The next earnings report is expected on 10 February 2027.